Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management.
J Nephrol
; 28(5): 641-5, 2015 Oct.
Article
em En
| MEDLINE
| ID: mdl-25712233
Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can be effectively treated by anti-C5 therapy, which controls complement activation. Treatment can be safely discontinued after complete remission and resolution of the precipitating cause, especially in patients with a low-risk genetic profile.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Complicações na Gravidez
/
Gerenciamento Clínico
/
Anticorpos Monoclonais Humanizados
/
Síndrome Hemolítico-Urêmica Atípica
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article